News items related to: Medicine Equality Now!
-
No Borders, No Barriers: Communities Call for Universal Access to Lenacapavir
Lenacapavir – a twice-yearly HIV prevention injection – could transform the fight against HIV. But Gilead’s restrictive voluntary license excludes...
-
Activists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP...
-
UN High-Level Meeting on NCDs: Declaration Without Affordability Is Just Empty Words
Weaknesses in the Draft Declaration Civil society groups warn that the latest draft does not reference the right of governments...
-
Procurement Non-Transparency, Overreliance on Donors, and Lacking Political Will for Local Production: Recent Africa Market Intelligence Analysis
The reports, published by the Kenya Legal and Ethical Issues Network on HIV and AIDS (KELIN – Kenya), Community Health...
-
ITPC Global Hosts Summit, Marking 30 years of Global Injustice
Organized by ITPC Global and the Make Medicines Affordable consortium, the summit brought together over 100 activists, policymakers, and researchers...
-
Brazil’s ABIA Leads Fight Against Patent Barriers to HIV, TB and Other Life-Saving Medicines
Through its Working Group on Intellectual Property (GTPI), ABIA has filed more than 40 oppositions since 2006 against patents on...
-
New Analysis Exposes Path to Affordable Lenacapavir for HIV Prevention
Lenacapavir, administered just twice a year, has been shown to reduce HIV transmission to nearly zero. However, the drug’s high...
-
An Earsplitting Silence: Pharma Makes Billions, Says Nothing About the Current Global Funding Crisis for HIV, Tuberculosis and Other Life-Threatening Illnesses
“It is shocking that the crisis facing the global HIV community has been met with such a resounding silence from...
-
‘A Matter of Life and Death’: Civil Society Groups Fight for Affordable DR-TB Treatment
“As the patent holder, Otsuka has prevented access to improved TB treatment due to its exorbitant prices. On World TB...
-
TNP+ is Successfully Opposing Big Pharma’s Hepatitis C Drug Monopoly
This win comes after years of campaigning by the AIDS Access Foundation (AAF) and the Thai Network of People Living...
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...